key: cord-0286258-xp1j52ic
authors: Verdume, L.; Danesh, G.; Trombert, S.; Sofonea, M. T.; Noel, V.; Foulongne, V.; Montes, B.; TUAILLON, E.; Haim-Boukobza, S.; Roquebert, B.; Alizon, S.
title: Spread of SARS-CoV-2 Delta variant infections bearing the S:E484Q and S:T95I mutations in July and August 2021 in France
date: 2021-09-16
journal: nan
DOI: 10.1101/2021.09.13.21263371
sha: 6fdae9aecc99189255f72f97e0cfd240fa1edcdc
doc_id: 286258
cord_uid: xp1j52ic

Analysing 92,598 variant screening tests performed on SARS-CoV-2 positive samples collected in France between 1 July and 31 August 2021 shows an increase of Kappa-like infections. Full genome sequencing reveals that these correspond to Delta variants bearing the S:E484Q mutation. Most of these sequences belong to a phylogenetic cluster and also bear the S:T95I mutation. Further monitoring is needed to determine if this trend is driven by undocumented superspreading events or an early signal of future viral evolutionary dynamics

using bwa v.0.7.17. Reads assemblage (megahit v1.2.9) and alignment (blast v2.9.0) were performed. A variant calling (freebayes v1.3.1) and annotation (snpEff v5.0) was carried out and a consensus sequence was constructed (ivar v1.3.1). Overall, we analysed 364 original full genome sequences.

The majority of the screening tests ( To analyse the temporal trend associated with the frequency of a given variant, we used the methods described in [6] and performed a multinomial regression using the Delta-like variant as a reference ( Table   2 ). The most striking effect we detected is that the few screening tests consistent with the Kappa variant appear to be strongly increasing with time in some French regions. The proportion of infections consistent with an Alpha variant was significantly decreasing over time in most French regions, which is consistent with the rapid spread of the Delta variant [6] .

Focusing on the tests consistent with a Kappa infection, the majority (33/49, i.e. 67%) originated from the Ile-de-France region (the Paris area) and the incidence globally increased from July to August 2021 (Supplementary Figure S2) . Following earlier studies [9, 10] , we assessed the change in relative frequencies of Kappa-consistent infections compared to Delta-consistent infections in the Ile-de-France region during August 2021. The results show that the former had a transmission advantage over the latter

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263371 doi: medRxiv preprint of 45% (95% confidence interval: 31 − 60%) ( Figure 1 ). Using an earlier starting date in July had little effect on the estimations ( Figure S3 ).

Full genome sequencing and analysis through the nextclade pipeline [11] revealed that all the samples (35/35, 100%) bearing the S:E484Q mutation and identified as potential Kappa were in fact Delta variants bearing the E484Q mutation.

We then aligned the sequences using mafft [12] , anonymised nucleotide position 23012 and performed a phylogenetic analysis using PhyML [13], using SMS to infer the substitution model [14] . The selected model was GTR+I+G. Strikingly, the majority of these Delta+E484Q sequences (28/35, 80%) clustered into the phylogeny into a clade ( Figure 2 ). Most of these sequences from this clade (29/35, 83%) originated from individuals residing in the Ile-de-France region and the information was missing for 2 sequences. In addition to S:E484Q, the phylogenetic cluster is associated with the following substitutions that are not found in half of the other Delta sequences: ORF1a:T403I, ORF1a:D1167N, ORF1b:A1219S, and S:T95I. The latter is present in some variants of interest, such as Iota, and has been reported in vaccine breakthrough infections [15] .

Finally, none of the individuals with Delta+E484Q reported travelling outside France 14 days before the sampling. As indicated above, nucleotide position 23,012, which is associated with the E484Q mutation, was ignored when performing the phylogenetic inference, meaning that the clustering originates from other mutations. Finally, based on the metadata analysis, there was no reported link between the 30 individuals from the phylogenetic cluster of interest (e.g. non were sequenced in the context of a transmission cluster). Note that two sequences in the cluster neither have the S:E484Q nor the S:T95I mutation. One possibility is the uncertainty in the phylogenetic reconstruction. Another could be the occurrence of genetic events such as recombination between two Delta lineages.

We report an increase in infections caused by Delta variants bearing the E484Q mutation in the Paris area. The significant transmission advantage we estimate for this mutation is consistent with it being associated with immune evasion [8] and with the high vaccination coverage in France [7] . Note that other lineages bearing a mutation in position S:484 were found to spread earlier in 2021 [16] but their transmission advantage was more limited (approximately 17% versus 35 to 63% here) and the reference strain was the Alpha variant, whereas is less contagious that the Delta variant [6] and has less immune evasion properties [5] .

Even if we detect a significant increasing trend, the Delta+E484Q samples represent a very small proportion of the tests performed. Therefore, the transmission advantage could be driven by an Figure S4) . In vitro studies using viral culture assays could be instrumental to understand this phenomenon. SARS-CoV-2 prevalence remains high and the beginning of the school term is likely to increase virus spread. Therefore, the alternative, more worrying, interpretation of these results, which is an adaptive advantage of a combination of the S:E484Q and S:T95I mutations, warrants close monitoring of these genomic patterns.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; 

All rights reserved. No reuse allowed without permission.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; 

All rights reserved. No reuse allowed without permission.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. sampling date number of kappa−like positive tests All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. date of origin of the temporal window (ends on Aug 31)) transmission advantage All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263371 doi: medRxiv preprint Figure S4 : Phylogeny showing sequences from the European countries (in yellow) and the 364 original sequences from the study. Sequences from the study bearing the S:E484Q mutation are in red, the others are in black. GISAID accession numbers will be provided upon publications.

q qq q q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qq q q q q q q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qq q q qq q q q q q q q q q q q q q q q q q q q q q q q qq q q q q q q q q q q qq q q q q q q q q q q q q q q q q q qq q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qq q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qq q qq q q q q q q q All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263371 doi: medRxiv preprint

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

New SARS-CoV-2 Variants -Clinical, Public Health, and Vaccine Implications

SARS-CoV-2 virulence evolution: avirulence theory, immunity, and trade-offs

Delta variant replication and immune evasion

Rapid spread of the SARS-CoV-2 Delta variant in some French regions

Coronavirus pandemic (COVID-19). Our World in Data

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

On measuring selection in experimental evolution